关于开发临床前候选物来对抗Helicobacter Pylori感染的研究
Haritha Dilip1, Deepika Khasa1, Ramya V K2
1Department of Chemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat 382055, India.
ACS infectious diseases
|July 19, 2025
概括
研究人员开发了新型的化胺和化胺,以对抗Helicobacter pylori (H. pylori) 感染. 这种有前途的化合物显示出对抗H. pylori生长的临床前开发潜力.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 微生物学 微生物学
背景情况:
- 杆菌 (H. pylori) 感染是一个重大的全球健康挑战,特别是在发展中国家,导致胃炎和胃癌.
- 针对H. pylori感染的现有治疗方法面临挑战,需要开发新型治疗剂.
研究的目的:
- 合成和评估一系列新型的基胺和基胺衍生物,作为潜在的抑制H. pylori生长的抑制剂.
- 识别和优化该系列中的化合物,以便进一步进行临床前开发.
主要方法:
- 采用一种新的,环保的合成途径,使用经济且易于获得的化学物质生产诺林/异诺林融合的胺衍生物.
- 合成的化合物被选,以检测它们在体外抑制H. pylori生长的能力.
- 优化研究是对已识别的最强大的抑制剂进行的.
主要成果:
- 合成方法成功地产生了与 pyridine 融合的胺衍生物,产量中等至良好.
- 几种合成的化合物表现出有前途的H. pylori生长抑制.
- 一个分子被确定并优化,证明了对H. pylori的显著抗菌潜力.
结论:
- 开发的化二二二二醇代表了一种有前途的新类化合物,用于对抗H. pylori感染.
- 鉴定的化合物需要进一步研究,并具有临床前开发的潜力.
- 具有成本效益和环保的合成方法使这些化合物对进一步研究和潜在的大规模生产具有吸引力.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
553
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
553
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
202
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
202
01:26Peptic Ulcer Disease IV: Management
146
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
146
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
528
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
528
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
583
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
583
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K